Vampire: The Masquerade - Bloodlines 2 has been delayed to October 2025

Paradox Interactive has confirmed that the long-awaited RPG Vampire: The Masquerade - Bloodlines 2 has been delayed once again to focus on "ensuring great technical quality."
The details:
The publisher announced the delay in a post on the game's website, confirming that it will now target an October release date due to its inability to meet the previous "first half of 2025" release window. "Paradox Interactive and The Chinese Room are committed to delivering this game, and we believe that ensuring great technical quality is more important than sticking to a specific date," Paradox wrote. "The game is currently in a late development stage, and feedback from the community has been taken into account during this time. The Chinese Room is working hard on quality assurance to ensure it is stable and free of bugs that could disrupt the player experience."
This marks the second delay for the game, having originally missed its late 2024 release window. While the game was "in a good enough place that we could have maintained our planned release window," developer The Chinese Room chose to push it back to 2025 in order to "prioritize polish" and provide a "quality assurance buffer."
Bloodlines 2, a sequel to the original 2004 cult classic RPG, was announced in 2019, with a PC and console release planned for the following year. Originally developed by Hardsuit Labs, the project has faced several setbacks, including Paradox's decision to distance itself from designer Chris Avellone due to sexual harassment allegations, as well as the dismissal of both the game's creative director and narrative designer. Hardsuit Labs was then dropped from the project, which was on the verge of being cancelled, while The Chinese Room took over development in 2023.
More gaming news:
Assassin's Creed Shadows is the franchise's second-biggest launch, trailing only 2020's AC: Valhalla.
Tomb Raider developer Crystal Dynamics has announced a wave of layoffs affecting 17 employees.